1. Contractors
  2. Auro Vaccines LLC

Auro Vaccines LLC

Federal contractor · Research and Development in Biotechnology (except Nanobiotechnology)

Auro Vaccines has 1 federal contract of $100,000 or more active since October 2023, with $10.7M obligated, from 1 agency. 1 is still running, 1 ending within 18 months.

Contracts
1 since FY2024$10,706,003 obligated, contracts of $100,000 or more
Running now
1 contract
Biggest customer
National Institutes of Health$10.7M on 1 contract
UEI
JCL5JKNMYAU5Unique entity ID in SAM.gov
Source
USAspending.govUpdated Nov 17, 2026, 7:02 PM UTC

Running contracts

Soonest end first. An agency may compete the work again, extend the contract or move it to another vehicle.

ContractObligatedEndsState
Advanced Development of Multivalent Vaccine Candidates for Filovirus and Lassa FeverNational Institutes of Health · 75N93020C00040$10,706,003Dec 31, 2026in 1 monthMD

End dates are the current period of performance; options not yet exercised can extend them. Each contract links to its record on USAspending.gov.

Who they work for

AgencyAmount
National Institutes of Health1 contract$10,706,003

What they sell

IndustryAmount
Research and Development in Biotechnology (except Nanobiotechnology)NAICS 541714 · 1 contract$10,706,003

Where the work is

Place of workAmount
Maryland1 contract$10,706,003

Source: USAspending.gov, prime contracts of $100,000 or more with an action since October 1, 2023. Department of Defense contracts appear there about 90 days after award. Other contracts ending soon at National Institutes of Health: see the list.

Get new notices like Auro Vaccines's work

New contract opportunities under NAICS 541714, research and development in biotechnology (except nanobiotechnology), the morning they appear. Free while in beta.

Free. We use your email only for these alerts and never share it. Privacy